Latrepirdine (Dimebon) – Kodiac biolabs

Our opinion on this compoundRetracted or disproven

30/100

High-profile phase 3 failure; residual probe value for multi-target receptor pharmacology only

Look, Latrepirdine is one of the most instructive failure stories in CNS pharmacology, and not in a way that makes it a compelling research target today. The 2008 Doody et al. phase 2 trial looked genuinely exciting: a small Russian cohort, significant ADAS-cog improvements, a multi-target receptor profile that nobody had properly characterized, and a mitochondrial protection story that felt like it could explain everything. Pfizer and Medivation saw it too, licensed it, and ran two large phase 3 trials. Both failed. CONNECTION and CONCERT were well-powered, well-designed trials and they found nothing. That’s not a marginal miss; thats a decisive refutation of the clinical hypothesis.

The mechanism story never really resolved. The proposed mitochondrial protective effects, seen in some Bhagya Bhardwaj and Bhatt lab preclinical work around 2009-2010, were speculative and never validated in humans. The receptor profile is genuinely broad: H1, alpha-1, alpha-2, 5-HT2A, 5-HT5A, 5-HT6, D1, D2. Interesting on paper. In practice, non-selective polypharmacology of this kind is hard to interrogate cleanly, and the carboline scaffold doesn’t give you the kind of selectivity you’d want for mechanistic studies. You can’t easily tease apart which receptor is doing what.

We think the only honest argument for latrepirdine as a research compound in 2025 is as a pharmacological probe for studying multi-receptor interaction effects in the receptor profile it occupies. Its beta-carboline scaffold is at least structurally distinct, and theres a small body of work using it to study 5-HT6 and 5-HT5A receptor contributions in mixed-target paradigms. For investigators specifically working on receptor polypharmacology or building multi-target binding models, it has some real but narrow utility. The compound is commercially available from several RUO vendors, synthesis is straightforward, and the pharmacokinetics are reasonably well characterized.

What we don’t like: the translational arrow points firmly backwards. The mitochondrial story is unvalidated and the primary indication collapsed publicly. The novelty is minimal, the differentiation from other available probes in its receptor class is low, and the evidence base that actually exists is evidence of failure. That phase 2 signal is almost certainly a statistical artifact or a trial design artifact; the Russian cohort, the small N, the endpoint choices. Investigators who want to study the receptor space latrepirdine occupies have better, cleaner probes available. This compound belongs in the case-study file, not on the active screening list.

Novelty: 25
Mechanism promise: 30
In-category differentiation: 20
Evidence quality: 55
Translational signal: 15
Research bench value: 40

Rationale Phase 3 CONNECTION and CONCERT trials decisively refuted the phase 2 signal in Alzheimer disease, collapsing the primary translational story; the compound retains narrow utility as a multi-target receptor probe by virtue of its carboline scaffold and unusual receptor breadth, but a serious investigator has no strong reason to prioritize it over better-validated tools.

Multi-target antihistamine / mitochondrial protectant

A Russian antihistamine repurposed for Alzheimer disease and Huntington disease; phase 3 trials failed despite encouraging phase 2 results.

Abstract

Latrepirdine (Dimebon, dimebolin; CAS 3613-73-8; molecular formula C21H25N3; molecular weight 319.45) is a tetrahydro-gamma-carboline antihistamine developed in the USSR in the 1960s and approved in Russia for allergic conditions. The compound is a non-selective receptor blocker (H1, alpha-1, alpha-2, 5-HT2A, 5-HT5A, 5-HT6, D1, D2). The Alzheimer disease application emerged from drug repurposing screens in the 2000s; preclinical studies suggested mitochondrial protective effects independent of the receptor binding. Phase 2 trial in mild-to-moderate Alzheimer disease (2008) demonstrated significant improvement in ADAS-cog and other endpoints, generating widespread interest. Phase 3 trials (CONNECTION, CONCERT) in 2010-2012 failed to replicate the phase 2 effects, marking one of the highest-profile late-stage failures in CNS drug development. The compound is no longer in clinical development. Used as a research compound for multi-target receptor pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-314Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.